Introduction: Cataract is the major cause of blindness in the developing world. Study aimed at evaluation of tear film stability and tear secretion after phacoemulsification compared with MSICS. Material and methods: This prospective comparative randomized study was performed in a tertiary centre of Jharkhand between June 2018 to March 2019. 187 patients with senile cataract were included in this study. Group A had 110 patients undergoing MSICS and group B 77 patients undergoing phacoemulsification. Dry eye symptoms(DES) characterizedby redness, burning, stinging, foreign body sensation, photophobia. Corneal fluorescein staining was performed. Basal Schirmer test was performed for assessment of aqueous tear production. Patients were examined post operatively on 1 st week, 4 th week and 3 rd month.
Results:Out of 187 patients 103(55.08%) were male and 84(44.91%) were female. Grade of DES increased significantly 1 week after each procedure compared to pre-operative data and remained increased after 4 weeks of surgery. After 3 months the symptoms decreased and returned to baseline data.Conclusion: MSICS is as effective as phacoemulsification with no difference between both techniques regarding tear film stability and tear secretion.
Introduction: Cataract is a major cause of impaired vision and blindness. Study aimed to find out if there is any association between dyslipidemia and cataract. Material and methods: This cross sectional hospital based study was performed in a tertiary care center of Jharkhand between June 2017 to March 2018. Total 223 patients who were diagnosed with senile cataract were included in the study. Detailed history, ophthalmologic and systemic examination was done. Dyslipidemia is defined as:Hypercholesterolemia (total cholesterol > 220 mg/dl), or Hypertriglyceridemia (total triglyceride > 150 mg/dl), or Low density lipoprotein > 130 mg/dl. Results: Out of total 223 patients 134 were men and 89 were women. 70% patients had dyslipidemia. Prevalence of dyslipidemia was associated significantly (< 0.05) with nuclear and cortical cataract but not significant (> 0.05) for posterior sub capsular cataract. Conclusion: Dyslipidemia maybe considered having an association with nuclear and cortical cataract directly or indirectly.
Background: The aim of the study was to evaluate the incidence of xerophthalmia in individuals with glaucoma by administering a topical regimen of antiglaucoma medication containing timolol and dorzolamide and to determine the frequency of ocular surface abnormalities among individuals with glaucoma who are undergoing treatment with topical antiglaucoma medications.
Methods: The study included a total of 75 participants of both genders. A total of 50 ocular units from 25 subjects under medication with two or more antiglaucoma agents for a period of six months were subjected to examination. Results: The study compared tear breakage time, Schirmer's test-1, and corneal staining score between the glaucoma cases and control groups. The mean values for tear breakage time were 9.44±2.76 seconds and 11.8±1.88 sec in the glaucoma and control group respectively (p=0.001). The mean values for Schirmer's test-1 were 7.63±2.64 mm and 12.86±1.93 mm in the glaucoma and control group respectively (p=0.001). The mean values for corneal staining score were 5.7±2.33 and 1.1±0.58 in the glaucoma and control group (p=0.001) respectively.
Conclusions: The prevalence of ocular surface disease and dry eye is higher among individuals undergoing antiglaucoma therapy. The application of glaucoma medication in the form of topical treatment has been associated with the development of dry eye syndrome and has been observed to affect the stability of the tear film.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.